


CORRIGENDUM

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. *J Eur Acad Dermatol Venereol* 2017.

In,¹ there was an error in Figure 5. The numbers of ADA-negative and ADA-positive patients at retreatment weeks 0 through 24 in the legend below the graph were inverted and should have read:



Reference

¹ Blauvelt A, Papp KA, Sofen H *et al*. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. *J Eur Acad Dermatol Venereol* 2017; **31**: 1004–1013.